Research progress of breast cancer with low HER2 expression
10.3760/cma.j.cn371439-20220609-00099
- VernacularTitle:HER2低表达乳腺癌研究进展
- Author:
Hangcheng XU
1
;
Yun WU
;
Jiayu WANG
Author Information
1. 国家癌症中心 国家肿瘤临床医学研究中心 中国医学科学院北京协和医学院肿瘤医院内科，北京 100021
- Keywords:
Breast neoplasms;
Prognosis;
Therapeutics;
Low expression of human epidermal growth factor receptor 2
- From:
Journal of International Oncology
2022;49(9):513-516
- CountryChina
- Language:Chinese
-
Abstract:
Breast cancer with low expression of human epidermal growth factor receptor 2 (HER2) has unique biological behaviors. Compared with HER2-zero breast cancer, there are significant differences in molecular subtype and gene expression between the two categories of breast cancer. Novel antibody-drug conjugates represented by T-DXd provide a new treatment option for patients with HER2-low breast cancer, and relevant clinical trials are continuing. At present, the relationship between HER2-low status and prognosis of breast cancer patients remains controversial. In-depth research into HER2-low breast cancer will help further improve clinical outcomes for this population.
